Streetbeat News

ZVSA

ZyVersa Therapeutics, Inc.

https://www.zyversa.com

Industry

Biotechnology

ZyVersa Therapeutics, Inc., a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. It engages in the development of VAR 200, a cholesterol efflux mediator to treat focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney disease; and IC 100, a novel inflammasome ASC inhibitor for treatment of multitude of inflammatory diseases. ZyVersa Therapeutics, Inc. is headquartered in Weston, Florida.

Open

0.59

Mkt cap

1.5M

Volume

6.1K

High

0.61

P/E Ratio

-0.07

52-wk high

8.05

Low

0.58

Div yield

N/A

52-wk low

0.58

ZyVersa Therapeutics (NASDAQ:ZVSA) reported a Q2 EPS of $(3.31), beating the analyst consensus estimate of $(3.75) by 11.73%. This represents a significant improvement over the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 09, 2024 | 8:40 pm

ZyVersa Therapeutics has announced the publication of data in a peer-reviewed journal demonstrating that extracellular ASC plays a crucial role in the aggregation and deposition of amyloid A fibrils, which are linked to chronic inflammatory conditions.

Portfolio Pulse from Benzinga Newsdesk

August 07, 2024 | 11:56 am

University of Miami researchers have published findings on ZyVersa Therapeutics' ASC Inhibitor, showing its potential as a biomarker for early cognitive decline detection in older adults.

Portfolio Pulse from Benzinga Newsdesk

July 29, 2024 | 11:47 am

ZyVersa Therapeutics, Inc. (NASDAQ: ZVSA) has selected obesity and related metabolic complications as the lead indication for its Inflammasome ASC Inhibitor IC 100. This decision marks a significant step in the company's development of first-in-class drugs for inflammatory and renal diseases.

Portfolio Pulse from Benzinga Newsdesk

July 25, 2024 | 12:00 pm

ZyVersa Therapeutics shares were halted on a circuit breaker due to a significant upward movement, with the stock now up 7.59%.

Portfolio Pulse from Benzinga Newsdesk

July 18, 2024 | 3:21 pm

ZyVersa Therapeutics published a paper in the Angiogenesis peer-review journal demonstrating that their Inflammasome ASC Inhibitor IC 100 restored retinal structure and function in an animal model of Retinopathy of Prematurity (ROP). The study showed that IC 100 suppressed retinal microglia activation, reduced retinal inflammation, and improved retinal function.

Portfolio Pulse from Benzinga Newsdesk

July 18, 2024 | 3:20 pm

ZyVersa Therapeutics (NYSE:ZVSA) has seen a significant decrease in its short interest, falling 96.61% since its last report. The company now has 15,000 shares sold short, which is 2.06% of its float. This is lower than the peer group average of 3.18%.

Portfolio Pulse from Benzinga Insights

May 21, 2024 | 7:15 pm

ZyVersa Therapeutics (NASDAQ:ZVSA) reported a Q1 2024 adjusted EPS of $(4.53), missing the analyst consensus estimate of $(3.70) by 22.43%.

Portfolio Pulse from Benzinga Newsdesk

May 15, 2024 | 12:37 pm

Clever Leaves Holdings Inc. announced its decision to voluntarily delist from Nasdaq, causing a 60% drop in its shares. Other stocks moved significantly in Monday's session, with Deciphera Pharmaceuticals surging 73% after an acquisition announcement, and various companies like Collective Audience and ImmunityBio also seeing substantial gains. Losers included Annovis Bio, down 57% after disappointing trial results, and Addex Therapeutics, falling 48.8% due to a failed epilepsy study.

Portfolio Pulse from Avi Kapoor

April 29, 2024 | 5:04 pm

ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) shares surged after announcing the publication of a scientific paper in 'Frontiers in Molecular Neuroscience'. The paper, authored by researchers from the University of Miami Miller School of Medicine, supports the use of ZyVersa's IC 100 to potentially reduce cardiac issues in Alzheimer's patients by inhibiting ASC inflammasomes. Additionally, ZyVersa executed a 1-for-20 reverse stock split last Friday, resulting in a float of less than 758,000 shares. The company does not pay dividends but engages in other capital allocation strategies.

Portfolio Pulse from Erica Kollmann

April 29, 2024 | 2:53 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.